Ascendis Pharma to Participate in the Oppenheimer 33rd Annual Healthcare Conference
11 March 2023 - 12:00AM
Ascendis Pharma A/S (Nasdaq: ASND) today announced that Jan
Mikkelsen, President & Chief Executive Officer, and Scott
Smith, Executive Vice President & Chief Financial Officer, will
participate in a virtual fireside chat at the Oppenheimer 33rd
Annual Healthcare Conference on Wednesday, March 15.
Details:
Event |
Oppenheimer 33rd Annual Healthcare Conference |
Location |
Virtual |
Date |
Wednesday, March 15, 2023 |
Time |
12:00-12:30 p.m. Eastern Time / 9:00-9:30 a.m. Pacific Time |
|
|
A live webcast of the event will be available via the Investors
& News section of the Ascendis Pharma website at
https://investors.ascendispharma.com. A webcast replay will also be
available on this website shortly after conclusion of the event for
30 days.
About Ascendis Pharma A/SAscendis Pharma is
applying its innovative TransCon platform to build a leading, fully
integrated, global biopharma company focused on making a meaningful
difference in patients’ lives. Guided by its core values of
patients, science and passion, the company uses its TransCon
technologies to create new and potentially best-in-class therapies.
Ascendis is headquartered in Copenhagen, Denmark, and has
additional facilities in Heidelberg, Berlin and Munich, Germany;
Palo Alto and Redwood City, California; and Princeton, New Jersey.
Please visit www.ascendispharma.com to learn more.
Forward-Looking Statements This press release
contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of
historical facts, included in this press release regarding
Ascendis’ future operations, plans and objectives of management are
forward-looking statements. Examples of such statements include,
but are not limited to, statements relating to (i) Ascendis’
ability to apply its TransCon platform to build a leading, fully
integrated, global biopharma company, and (ii) Ascendis’ use of its
TransCon technologies to create new and potentially best-in-class
therapies. Ascendis may not actually achieve the plans, carry out
the intentions or meet the expectations or projections disclosed in
the forward-looking statements and you should not place undue
reliance on these forward-looking statements. Actual results or
events could differ materially from the plans, intentions,
expectations and projections disclosed in the forward-looking
statements. Various important factors could cause actual results or
events to differ materially from the forward-looking statements
that Ascendis makes, including the following: dependence on third
party manufacturers, distributors, and service providers for
Ascendis products and product candidates; unforeseen safety or
efficacy results in its development programs or on-market products;
unforeseen expenses related to commercialization of any approved
Ascendis products; expenses related to Ascendis’ development
programs; unforeseen selling, general and administrative expenses,
other research and development expenses and Ascendis’ business
generally; delays in the development of its programs related to
manufacturing, regulatory requirements, speed of patient
recruitment or other unforeseen delays; Ascendis’ ability to obtain
additional funding, if needed, to support its business activities;
the impact of international economic, political, legal, compliance,
social and business factors, including inflation, and the effects
on its business from the worldwide COVID-19 pandemic and the
ongoing conflict in the region surrounding Ukraine and Russia. For
a further description of the risks and uncertainties that could
cause actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to Ascendis’
business in general, see Ascendis’ Annual Report on Form 20-F filed
with the U.S. Securities and Exchange Commission (SEC) on February
16, 2023 and Ascendis’ other future reports filed with, or
submitted to, the SEC. Forward-looking statements do not reflect
the potential impact of any future licensing, collaborations,
acquisitions, mergers, dispositions, joint ventures, or investments
that Ascendis may enter into or make. Ascendis does not assume any
obligation to update any forward-looking statements, except as
required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company
logo and TransCon are trademarks owned by the Ascendis Pharma
Group. © March 2023 Ascendis Pharma A/S.
Investor Contacts: |
|
Media Contact: |
Tim Lee |
|
Melinda Baker |
Ascendis Pharma |
|
Ascendis Pharma |
+1 (650) 374-6343 |
|
+1 (650) 709-8875 |
tle@ascendispharma.com |
|
media@ascendispharma.com |
ir@ascendispharma.com |
|
|
|
|
|
Patti Bank |
|
|
ICR Westwicke |
|
|
+1 (415) 513-1284 |
|
|
patti.bank@westwicke.com |
|
|
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Apr 2023 to Apr 2024